{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-047913","form_type":"8-K","ticker":"SWKHL","cik":"0001089907","company_name":"SWK Holdings Corp","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.632984+00:00","generated_at":"2026-05-30T00:14:05.192733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"SWK Holdings Reports Q3 2024 Net Income of $3.5 Million, Revenue Up 15.6%","bullets":["Q3 2024 GAAP net income was $3.5 million, compared to $4.5 million in Q3 2023.","Total revenue increased 15.6% to $10.4 million, driven by finance receivables segment.","Net finance receivables grew 14.4% to $255.9 million as of September 30, 2024.","Closed $11.0 million royalty financing with Relief Therapeutics and $25.7 million amendment with Eton Pharmaceuticals.","GAAP book value per share rose 3.7% to $22.94; repurchased ~340,000 shares YTD for $5.8 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-047913","json":"https://secwatch.observer/filing/0001628280-24-047913.json","markdown":"https://secwatch.observer/filing/0001628280-24-047913.md","text":"https://secwatch.observer/filing/0001628280-24-047913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1089907/000162828024047913/0001628280-24-047913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1089907/000162828024047913/swkh-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:14:05.192733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}